Advancements in cardiac gene editing are poised to reshape the landscape of cardiovascular medicine. This groundbreaking field involves the precise modification of the genetic code within cardiac cells, offering a revolutionary approach to addressing the root causes of heart diseases. Molecular tools such as CRISPR-Cas9 are at the forefront, enabling researchers to target and edit specific genes linked to cardiovascular conditions. This transformative technology holds the potential to usher in personalized therapeutic interventions, opening new vistas for treating congenital heart disorders, genetic predispositions, and various cardiovascular ailments. Although still in the nascent stages of development, cardiac gene editing represents a cutting-edge avenue that not only enhances our understanding of cardiac health but also holds immense promise for pioneering tailored treatments for individuals with diverse cardiovascular conditions.
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical Center, United States
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : CARDIAC TROPONIN AND HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH DIALYSIS VINTAGE AND CARDIOVASCULAR COMORBIDITY
Sofra Maria, Aretaieion University Hospital, Greece
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation